Toll-like Receptor 7/8 Agonists Exert Antitumor Effect in a Mouse Melanoma Model
Medicina · 2026
DOI: 10.3390/medicina62010141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicina, 2026. Verfasst von Gheorghita Isvoranu und 8 weiteren Autor:innen. Beteiligte Einrichtung: 'Victor Babeș' National Institute of Pathology, 050096 Bucharest, Romania. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Toll-Like Receptor 8, Antineoplastic Agents, Melanoma. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Romanian Ministry of Education and Research and CNCS-UEFISCDI.
Abstract (Originalsprache)
Background and Objectives: Toll-like receptors (TLRs) are pattern recognition receptors with an essential role in regulating both the innate and adaptive immune response. Given their pleiotropic effects in mounting an immune response, previous studies have proposed targeting these TLRs might render alternative strategies for cancer therapy. Synthetic immune response modifiers, such as imidazoquinolines, stimulate the immune cells by activating Toll-like receptors, particularly TLR7/8 receptors, consequently mounting an immune response. Agonists of this class activate, via TLR-mediated signaling, dendritic and B cells, as well as myeloid cells and T cells, thus exhibiting good prospects for cancer immunotherapy. In the present study, we sought to evaluate the effect of imiquimod and gardiquimod, two TLR 7 and 7/8 agonists, respectively, on tumor growth and phenotype of NK cells associated with melanoma. Materials and Methods: We generated a syngeneic model of melanoma in C57BL/6J mice by subcutaneously injecting murine melanoma cells and monitoring tumor growth. Starting on day 8 or 14, we applied TLR agonists either intratumorally or topically and followed the tumor dynamics and NK cell-associated pattern.
Results
Our results suggest that both TLR agonists displayed an antitumor effect along with a phenotypically activated profile of NK cells. Both imiquimod and gardiquimod treatment inhibited tumor growth, with gardiquimod showing an increased potency compared to imiquimod.
Conclusions
This implies that TLR agonists like imiquimod and gardiquimod could serve as neoadjuvant, adjuvant, or complementary immunotherapeutic agents in melanoma therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 'Victor Babeș' National Institute of Pathology, 050096 Bucharest, Romania.
- Institute of Biochemistry of the Romanian Academy, 060031 Bucharest, Romania.
ORCID-Profile: Gheorghita Isvoranu, Ana-Maria Enciu, Monica Neagu, Gabriela Chiritoiu, Cristian V A Munteanu, Marioara Chiritoiu-Butnaru
Förderung
- Romanian Ministry of Education and Research and CNCS-UEFISCDI
Zitieren
APA
Isvoranu, G., Surcel, M., Enciu, A. M., Munteanu, A. N., Neagu, M., Niculae, A. M., Chiritoiu, G., Munteanu, C. V. A., & Chiritoiu-Butnaru, M. (2026). Toll-like Receptor 7/8 Agonists Exert Antitumor Effect in a Mouse Melanoma Model. Medicina. https://doi.org/10.3390/medicina62010141
Vancouver
Isvoranu G, Surcel M, Enciu AM, Munteanu AN, Neagu M, Niculae AM, et al. Toll-like Receptor 7/8 Agonists Exert Antitumor Effect in a Mouse Melanoma Model. Medicina. 2026. doi:10.3390/medicina62010141
BibTeX
@article{Isvoranu2026,
author = {Isvoranu, Gheorghita and Surcel, Mihaela and Enciu, Ana-Maria and Munteanu, Adriana Narcisa and Neagu, Monica and Niculae, Andrei Marian and Chiritoiu, Gabriela and Munteanu, Cristian V A and Chiritoiu-Butnaru, Marioara},
title = {Toll-like Receptor 7/8 Agonists Exert Antitumor Effect in a Mouse Melanoma Model},
journal = {Medicina},
year = {2026},
doi = {10.3390/medicina62010141}
}
EUVIMED